<i>CRLF2</i> -rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapy
Sara Silbert, Samantha Scanlon, Hao‐Wei Wang, Constance M. Yuan, Alyssa Doverte, Jake Wellek, Nisha Patel, Raul C. Braylan, Mark A. Ahlman, Evrim Türkbey, Sandra D. Bohling, Karen M. Chisholm, Murat Alp Öztek, Mike LaLoggia, Anupam Verma, Haneen Shalabi, Alexandra E. Kovach, Brent L. Wood, Adam J. Lamble, Ilan Kirsch, Kasey J. Leger, Nirali N. Shah
Abstract
Lineage switch (LS) refers to the immunophenotypic transformation of one leukemia lineage to another (ie, lymphoid to myeloid) with retention of baseline genetics. This phenomenon was originally observed in infants with B-lymphoblastic leukemia (B-ALL) with KMT2A rearrangements following chemotherapy, but is now increasingly being observed as a form of immune escape following targeted therapies among children and adults with B-ALL with and without KMT2A rearrangements. In this report, we present two cases of adolescents with B-ALL harboring CRLF2 rearrangements (Philadelphia-like phenotype) who developed LS to acute myeloid leukemia following CD19 targeted therapy. To our knowledge, these are the first cases of LS to be reported in patients with CRLF2 rearranged acute lymphoblastic leukemia. In addition to raising awareness that this genetic mutation may associate with lineage plasticity, our cases illustrate the importance of multi-modal disease surveillance in the diagnosis of LS.